(Post-pandemic Era)-Global Hepatitis Drugs Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Report Code : XYZ2131717
- Published On: Nov, 2020
- Category : Medical Devices
- Pages : 111
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research team published a report for global Hepatitis Drugs market in this environment.
In terms of revenue, this research report indicated that the global Hepatitis Drugs market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Hepatitis Drugs industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The GlaxoSmithKline aims at producing XX Hepatitis Drugs in 2020, with XX % production to take place in global market, Johnson & Johnson accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Hepatitis Drugs Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Hepatitis Drugs Market
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis
F. Hoffmann-La Roche
Arbutus Biopharma
Janssen Pharmaceuticals
Bristol-Myers Squibb
Gilead Sciences
Vertex Pharmaceuticals
Abbvie
Achillion Pharmaceuticals
Dynavax Technologies
Mitsubishi Tanabe Pharma
Major Type of Hepatitis Drugs Covered in report:
Oral
Injection
Application Segments Covered in report
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Hepatitis Drugs market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Hepatitis Drugs Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 Oral -Product Introduction and Major Manufacturers
1.1.2 Injection -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Hepatitis Drugs Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis3.1 China Hepatitis Drugs Market
3.1.1 Top Companies leading Hepatitis Drugs Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)3.2 EU Hepatitis Drugs Market
3.2.1 Top Companies leading Hepatitis Drugs Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)3.3 USA Hepatitis Drugs Market
3.3.1 Top Companies leading Hepatitis Drugs Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)3.4 Japan Hepatitis Drugs Market
3.4.1 Top Companies leading Hepatitis Drugs Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)3.5 India Hepatitis Drugs Market
3.5.1 Top Companies leading Hepatitis Drugs Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)3.6 Southeast Asia Hepatitis Drugs Market
3.6.1 Top Companies leading Hepatitis Drugs Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Hepatitis Drugs Market
3.7.1 Top Companies leading Hepatitis Drugs Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Hepatitis Drugs Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)4.1 Hepatitis Drugs Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Hepatitis Drugs Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)5.1 Global Hepatitis Drugs Sales and Growth Rate (2021-2026)
5.2 Global Hepatitis Drugs Sales Value and Growth Rate (2021-2026)
6 Hepatitis Drugs Competitive Analysis6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Company Profiles
6.1.2 GlaxoSmithKline Product Introduction
6.1.3 GlaxoSmithKline Hepatitis Drugs Production, Revenue (2015-2020)
6.1.4 SWOT Analysis6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Company Profiles
6.2.2 Johnson & Johnson Product Introduction
6.2.3 Johnson & Johnson Hepatitis Drugs Production, Revenue (2015-2020)
6.2.4 SWOT Analysis6.3 Merck
6.3.1 Merck Company Profiles
6.3.2 Merck Product Introduction
6.3.3 Merck Hepatitis Drugs Production, Revenue (2015-2020)
6.3.4 SWOT Analysis6.4 Novartis
6.4.1 Novartis Company Profiles
6.4.2 Novartis Product Introduction
6.4.3 Novartis Hepatitis Drugs Production, Revenue (2015-2020)
6.4.4 SWOT Analysis6.5 F. Hoffmann-La Roche
6.5.1 F. Hoffmann-La Roche Company Profiles
6.5.2 F. Hoffmann-La Roche Product Introduction
6.5.3 F. Hoffmann-La Roche Hepatitis Drugs Production, Revenue (2015-2020)
6.5.4 SWOT Analysis6.6 Arbutus Biopharma
6.6.1 Arbutus Biopharma Company Profiles
6.6.2 Arbutus Biopharma Product Introduction
6.6.3 Arbutus Biopharma Hepatitis Drugs Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Janssen Pharmaceuticals
6.7.1 Janssen Pharmaceuticals Company Profiles
6.7.2 Janssen Pharmaceuticals Product Introduction
6.7.3 Janssen Pharmaceuticals Hepatitis Drugs Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Bristol-Myers Squibb
6.8.1 Bristol-Myers Squibb Company Profiles
6.8.2 Bristol-Myers Squibb Product Introduction
6.8.3 Bristol-Myers Squibb Hepatitis Drugs Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Gilead Sciences
6.9.1 Gilead Sciences Company Profiles
6.9.2 Gilead Sciences Product Introduction
6.9.3 Gilead Sciences Hepatitis Drugs Production, Revenue (2015-2020)
6.9.4 SWOT Analysis6.10 Vertex Pharmaceuticals
6.10.1 Vertex Pharmaceuticals Company Profiles
6.10.2 Vertex Pharmaceuticals Product Introduction
6.10.3 Vertex Pharmaceuticals Hepatitis Drugs Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Abbvie
6.12 Achillion Pharmaceuticals
6.13 Dynavax Technologies
6.14 Mitsubishi Tanabe Pharma
7 Conclusion
-
The (Post pandemic Era) Global Hepatitis Drugs Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the (Post pandemic Era) Global Hepatitis Drugs Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
From 2024 to 2029, the (Post pandemic Era) Global Hepatitis Drugs Market is expected to grow at a compound annual growth rate of YY%, reaching a value of USD XXX Million.
The influx of capital into the (Post pandemic Era) Global Hepatitis Drugs Market, as well as the deployment of technologies designed to increase efficiency and yield high volume, are paving the way for promising market opportunities.
The (Post pandemic Era) Global Hepatitis Drugs Market is expected to reach a considerable market valuation.